依达拉奉右莰醇治疗血管介入术后急性脑梗死的疗效及对血液流变学和血清Lp-PLA2 NSE水平的影响OACSTPCD

Objective To investigate the clinical effect of edaravone-dexcamphorol in the treatment of ACI after vascular intervention,and the effect on the hemorheology and serum Lp-PLA2 and NSE levels.Methods Totally 120 ACI patients received vascular intervention surgery in Shanxi Prouincial People's Hospital from January 2020 to January 2023 were selected and divided into the matched group and the combination group based on different postoperative treatment plans,with 60 patients in each group.The matched group received routine treatment,while the combination group received edaravone-dexborneol in addition to the matched group.The clinical efficacy,hemorheology,changes in serum Lp-PLA2 and NSE levels between the two groups were evaluated and compared.Results The score of NIHSS at all observation points(7 days,14 days and 6 months after surgery)in the two groups was lower than before surgery(P<0.05),and the combination group were lower(P<0.05).The total effective rate of combination group was 93.33%,which was higher than 75.00%of matched group(P<0.05).There was no significant difference in hemorheology indexes between the two groups before surgery(P>0.05),but PV,whole blood HSV and LSV at 14 days after surgery in the combination group were lower than matched group(P<0.05).Serum Lp-PLA2 and NSE levels at 14 days after surgery in the two groups decreased(P<0.05),and those in combination group were lower(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).After 6 months of treatment,the overall incidence of adverse outcomes in the combination group was 3.33%,which was lower than 18.33%in the matched group(P<0.05).Conclusion The application of edaravone-dexborneol after vascular intervention can significantly improve the therapeutic effect of ACI,improve patients'neurological function and hemorheology,regulate serum Lp-PLA2 and NSE levels,and reduce adverse outcomes.